Vaxxel develops novel and proprietary live-attenuated vaccines candidate against bronchiolitis and pneumonia and in particular against human Metnapneumovirus and against human Respiratory Virus. Vaxxel is a spin off fom Virpath, the virology and human pathology Laboratory of the University Claude Bernard in Lyon (UCBL), France, and has been founded by Dr. Manuel Rosa-Calatrava Co-Director of Virpath (Lyon), Pr. Guy Boivin of the University of Laval (Quebec), by Denis Cavert, President of Vaxxel.
Company Details
- Employees
- 10
- Founded
- 2019
- Address
- 43, Boulevard Du 11 Novembre 1918, Villeurbanne,auvergne-Rhône-Alpes 69100,france
- co****@****xxel.fr
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- vaxxel.fr
- HQ
- Villeurbanne, Auvergne-Rhône-Alpes
Vaxxel Questions
Vaxxel's website is vaxxel.fr
Vaxxel's LinkedIn profile is https://fr.linkedin.com/company/vaxxel
Vaxxel has
10 employees.
View email and phone details for 10
employees at Vaxxel.
Vaxxel's industry is
Pharmaceutical Manufacturing
Vaxxel's top competitors are
Virexpr,
Antineo,
Misutech,
Faactopi,
Reventus Pharma,
Trienix Pharma,
Gaoma Therapeutics,
Minitrucks Robotics,
Austral Dx,
Virnext.
Vaxxel's support email address is contact@vaxxel.fr
Vaxxel's categories are Pharmaceutical Manufacturing
Vaxxel's founding year is 2019
